Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry
Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Ridhima Goel, Johny Nicolas, Birgit Vogel, Clayton Snyder, Annapoorna Kini, Carlo Briguori, Bernhard Witzenbichler, Ioannis Iakovou, Gennaro Sardella, Kevin Marzo, Anthony DeFranco, Thomas Stuckey, Alaide Chieffo, Antonio Colombo, Richard Shlofmitz, Davide Capodanno, George Dangas, Stuart Pocock, Roxana Mehran, Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Ridhima Goel, Johny Nicolas, Birgit Vogel, Clayton Snyder, Annapoorna Kini, Carlo Briguori, Bernhard Witzenbichler, Ioannis Iakovou, Gennaro Sardella, Kevin Marzo, Anthony DeFranco, Thomas Stuckey, Alaide Chieffo, Antonio Colombo, Richard Shlofmitz, Davide Capodanno, George Dangas, Stuart Pocock, Roxana Mehran
Abstract
Background: Managing percutaneous coronary intervention (PCI) patients with atrial fibrillation (AF) presents challenges given that there are several potential antithrombotic therapy (ATT) strategies.
Aims: We examined ATT patterns, agreement between subjective physician ratings and validated risk scores, physician-patient perceptions influencing ATT and 1-year outcomes.
Methods: The AVIATOR 2 prospective registry enrolled 514 non-valvular AF-PCI patients from 11 sites. Treating physicians selected ATT and completed smartphone surveys rating stroke and bleeding risks, compared against CHA2DS2-VASc and HAS-BLED scores. Patients completed surveys regarding treatment understanding. Primary outcomes were 1-year major adverse cardiac or cerebrovascular events (MACCE: composite of death, myocardial infarction, definite/probable stent thrombosis, stroke, target lesion revascularisation) and actionable bleeding (Bleeding Academic Research Consortium 2, 3 or 5).
Results: The mean patient age was 73.2±9.0 years, including 25.8% females. Triple therapy (TT: 1 anticoagulant and 2 antiplatelet agents) was prescribed in 66.5%, dual antiplatelet therapy (DAPT) in 20.7% and dual therapy (1 anticoagulant+1 antiplatelet agent) in 12.8% of patients. Physician ratings and validated risk scores showed poor agreement (stroke: kappa=0.03; bleeding: kappa=0.07). Physicians rated bleeding-related safety (93.8%) as the main factor affecting ATT choice. Patients worried about stroke over bleeding (50.6% vs 14.8%). No group differences by ATT strategy were observed in 1-year MACCE (TT 14.1% vs dual therapy 12.7% vs DAPT 18.5%; p=0.25), or actionable bleeding (14.7% vs 7.9% vs 15.1%, respectively; p=0.89).
Conclusions: The AVIATOR 2 study is the first digital health study examining physician-patient perspectives on ATT choices after AF-PCI. TT was the most common strategy without differences in 1-year outcomes in ATT strategy. Physicians rated safety first when prescribing ATT; patients feared stroke over bleeding.
Clinicaltrials: gov: NCT02362659.
Source: PubMed